Croda International (CRDA)

Sector:

Industrial Chemicals

Index:

FTSE 100

NULL
   
  • Closing Price Chg:
    -49.00p
  • 52 Week High: NULL
  • 52 Week Low: 2,623.00p
  • Currency: UK Pounds
  • Shares Issued: 139.64m
  • Volume: 0
  • RiskGrade: 108

Croda warns on margins as profits slump on weak demand

By Frank Prenesti

Date: Tuesday 27 Feb 2024

LONDON (ShareCast) - (Sharecast News) - British speciality chemicals maker Croda International on Tuesday warned of lower operating margins this year after posting a slump in 2023 profits due to customers destocking and a weak macroeconomic environment.
Pre-tax profit for the year to December 31 fell 69.7% to £236.3m. The company, which supplies the consumer and life sciences industries, said it expected group adjusted operating margin to be two to three percentage points lower and adjusted profit before tax to be between £260m and £300m in full year 2024.

The FTSE 100-listed company benefited greatly from the Covid-19 pandemic, including making the lipids for the Pfizer-BioNTech vaccine. However, as supply chains began to constrict after lockdowns eased customers built up stock to cope with the post-crisis surge in orders.

This led Croda to cut full-year forecasts last October, with adjusted pre-tax profit expected to come in at £300m - £320m, down from previous guidance of £370m - £400m. The 2023 figure came in at the low end at £308m but beat the £300m consensus of analyst estimates compiled by the company.

"Given the ongoing uncertainty in our end markets, the recovery trajectory for each of our business units remains difficult to predict and the range of possible outcomes in 2024 is therefore wider than usual at this stage of the year," Croda said.

"Overall, however, the Group expects to deliver mid to high single digit percentage sales growth in 2024, excluding the $60m of Covid-19 lipid sales in 2023, with higher sales volumes more than offsetting lower price/mix."

It added that its consumer care division had started the year well and the board was "cautiously optimistic" about the improving demand trend we experienced January.

"Within Life Sciences, we expect the non-Covid pharma business to grow but that destocking will continue in crop protection. Demand in industrial specialties is expected to remain weak."

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

CRDA Market Data

Currency UK Pounds
Share Price NULL
Closing Price Change -49.00p
% Change 0.00 %
52 Week High NULL
52 Week Low 2,623.00p
Volume 0
Shares Issued 139.64m
RiskGrade 108

CRDA Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
51.37% below the market average51.37% below the market average51.37% below the market average51.37% below the market average51.37% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Price Trend
74.95% below the market average74.95% below the market average74.95% below the market average74.95% below the market average74.95% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Income
31.85% above the market average31.85% above the market average31.85% above the market average31.85% above the market average31.85% above the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average
Growth
92.6% below the market average92.6% below the market average92.6% below the market average92.6% below the market average92.6% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average

What The Brokers Say

Strong Buy 5
Buy 1
Neutral 6
Sell 1
Strong Sell 1
Total 14
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CRDA Dividends

  Latest Previous
  Interim Final
Ex-Div 28-Aug-25 10-Apr-25
Paid 07-Oct-25 28-May-25
Amount 48.00p 63.00p

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

CRDA Key Personnel

CFO Stephen Oxley

Top of Page